Literature DB >> 8419467

Regulation of IFN-gamma and tumor necrosis factor-alpha expression in vivo. Effects of cycloheximide and cyclosporine in normal and lipopolysaccharide-treated mice.

S M Cockfield1, V Ramassar, P F Halloran.   

Abstract

Despite accumulating information about cytokine expression in vitro, relatively little is known about the regulation and biologic relevance of these mediators in vivo. In order to study the effects of inhibition of protein synthesis and cyclosporine in vivo, we made use of systemically administered LPS, which induces the expression of a variety of cytokines. The expression of IFN-gamma and TNF-alpha mRNA in normal and LPS-treated mice was examined by Northern blot analysis and amplification using the polymerase chain reaction. IFN-gamma activity was monitored using the biologic end point of MHC induction. TNF-alpha activity in serum was assessed using a L929 cytotoxicity assay. Messenger RNA for IFN-gamma and TNF-alpha could not be reliably detected by Northern analysis in spleens or kidneys of normal mice. After treatment with cycloheximide, a protein synthesis inhibitor, IFN-gamma and TNF-alpha mRNA could be detected in both sites in otherwise normal mice. The level of both IFN-gamma and TNF-alpha mRNA increased after LPS, although the temporal patterns of expression were different. The concurrent administration of cycloheximide led to marked superinduction of both cytokine mRNA levels. Similar effects were seen in T cell-deficient nude mice, suggesting that these responses are T cell independent. Cyclosporin A blocked induction of IFN-gamma in a dose dependent manner, but failed to significantly inhibit TNF-alpha mRNA or protein expression. Thus at least part of the immunosuppressive effect of cyclosporin A in vivo may be caused by its ability to inhibit the expression of certain cytokine genes, as has been found in vitro systems. However, the cellular target for this effect may extend to cell populations other than T cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8419467

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  Upregulation of lymphoid and renal interferon-gamma mRNA in autoimmune MRL-Fas(lpr) mice with lupus nephritis.

Authors:  X Fan; R P Wüthrich
Journal:  Inflammation       Date:  1997-02       Impact factor: 4.092

Review 2.  Involvement of tumor necrosis factor-alpha in glomerular injury.

Authors:  L Baud; B Fouqueray; C Philipp
Journal:  Springer Semin Immunopathol       Date:  1994

3.  Role of T cells and gamma interferon during induction of hypersensitivity to lipopolysaccharide by toxic shock syndrome toxin 1 in mice.

Authors:  M M Dinges; P M Schlievert
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

4.  Monophosphoryl lipid A behaves as a T-cell-independent type 1 carrier for hapten-specific antibody responses in mice.

Authors:  K R Myers; P Beining; M Betts; H Snippe; J Inman; B Golding
Journal:  Infect Immun       Date:  1995-01       Impact factor: 3.441

5.  A case of multicentric Castleman's disease having lung lesion successfully treated with humanized anti-interleukin-6 receptor antibody, tocilizumab.

Authors:  Tomoaki Higuchi; Takashi Nakanishi; Kunio Takada; Mitsuyo Matsumoto; Makoto Okada; Hideyuki Horikoshi; Kimihiro Suzuki
Journal:  J Korean Med Sci       Date:  2010-08-12       Impact factor: 2.153

6.  Mouse hepatitis virus infection upregulates genes involved in innate immune responses.

Authors:  Dhriti Chatterjee; Sankar Addya; Reas S Khan; Lawrence C Kenyon; Alexander Choe; Randall J Cohrs; Kenneth S Shindler; Jayasri Das Sarma
Journal:  PLoS One       Date:  2014-10-31       Impact factor: 3.240

7.  Interferon gamma receptor deficient mice are resistant to endotoxic shock.

Authors:  B D Car; V M Eng; B Schnyder; L Ozmen; S Huang; P Gallay; D Heumann; M Aguet; B Ryffel
Journal:  J Exp Med       Date:  1994-05-01       Impact factor: 14.307

Review 8.  The regulation of pulmonary immunity.

Authors:  M F Lipscomb; D E Bice; C R Lyons; M R Schuyler; D Wilkes
Journal:  Adv Immunol       Date:  1995       Impact factor: 3.543

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.